71 related articles for article (PubMed ID: 16140069)
1. An On-Treatment Decreased Trend of Serum IL-6 and IL-8 as Predictive Markers Quickly Reflects Short-Term Efficacy of PD-1 Blockade Immunochemotherapy in Patients with Advanced Gastric Cancer.
Liu J; Mao Y; Mao C; Wang D; Dong L; Zhu W
J Immunol Res; 2024; 2024():3604935. PubMed ID: 38774604
[TBL] [Abstract][Full Text] [Related]
2. Predicting Recurrence After Radical Surgery for High-Risk Renal Cell Carcinoma: Development and Internal Validation of the "TOWARDS" Score.
Ishiyama Y; Omae K; Kondo T; Yoshida K; Iizuka J; Takagi T
Ann Surg Oncol; 2024 May; 31(5):3513-3522. PubMed ID: 38285306
[TBL] [Abstract][Full Text] [Related]
3. Does nivolumab combined with fluorouracil-based chemotherapy produce higher objective response rate than other immunochemotherapy regimes in metastatic esophageal cancer?
Li Y; Shen L; Yin X; Chen Z; Chen Y
Lancet Reg Health West Pac; 2023 Oct; 39():100926. PubMed ID: 37822732
[No Abstract] [Full Text] [Related]
4. Does nivolumab combined with fluorouracil-based chemotherapy produce higher objective response rate than other immunochemotherapy regimes in metastatic esophageal cancer?: authors reply.
Gao Z; Huang S; Wang S; Tang D; Xu W; Zeng R; Qiao G
Lancet Reg Health West Pac; 2023 Oct; 39():100927. PubMed ID: 37868211
[No Abstract] [Full Text] [Related]
5. Correction: Predictive progression outcomes and risk stratification in patients with recurrent or metastatic nasopharyngeal carcinoma who received first‑line immunochemotherapy.
He D; Zhang Y; He S; Zhang Y; Dai K; Xu C; Huang Y
Clin Transl Oncol; 2024 May; 26(5):1280-1282. PubMed ID: 38416316
[No Abstract] [Full Text] [Related]
6. Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial.
Chamie K; Donin NM; Klöpfer P; Bevan P; Fall B; Wilhelm O; Störkel S; Said J; Gambla M; Hawkins RE; Jankilevich G; Kapoor A; Kopyltsov E; Staehler M; Taari K; Wainstein AJA; Pantuck AJ; Belldegrun AS
JAMA Oncol; 2017 Jul; 3(7):913-920. PubMed ID: 27787547
[TBL] [Abstract][Full Text] [Related]
7. Overview of Current and Future Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma.
Nandagopal L; Naik G; Sonpavde G
Curr Treat Options Oncol; 2018 Jan; 19(1):2. PubMed ID: 29349592
[TBL] [Abstract][Full Text] [Related]
8. Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality?
Taguchi S; Buti S; Fukuhara H; Otsuka M; Bersanelli M; Morikawa T; Miyazaki H; Nakagawa T; Fujimura T; Kume H; Igawa Y; Homma Y
PLoS One; 2017; 12(2):e0172341. PubMed ID: 28241027
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant and neoadjuvant therapy in renal cell carcinoma.
Choueiri M; Tannir N; Jonasch E
Curr Clin Pharmacol; 2011 Aug; 6(3):144-50. PubMed ID: 21827393
[TBL] [Abstract][Full Text] [Related]
10. Cytoreductive nephrectomy in metastatic renal cell carcinoma.
Healy KA; Marshall FF; Ogan K
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1295-304. PubMed ID: 16925495
[TBL] [Abstract][Full Text] [Related]
11. Systemic therapy for renal cell carcinoma.
Motzer RJ; Russo P
J Urol; 2000 Feb; 163(2):408-17. PubMed ID: 10647643
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant interleukin-2, interferon-alpha, and 5-fluorouracil immunochemotherapy after radical nephrectomy for locally advanced renal cell carcinoma.
Hong SK; Kwak C; Lee SE
Urology; 2005 Sep; 66(3):518-22. PubMed ID: 16140069
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-2, interferon-alpha, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma: a prospective phase II study: the experience of Rambam and Lin Medical Centers 1996-2000.
Gez E; Rubinov R; Gaitini D; Meretyk S; Best LA; Native O; Stein A; Erlich N; Beny A; Zidan J; Haim N; Kuten A
Cancer; 2002 Oct; 95(8):1644-9. PubMed ID: 12365011
[TBL] [Abstract][Full Text] [Related]
14. Does radical nephrectomy with immunochemotherapy have any superiority over embolization alone in metastatic renal cell carcinoma? A preliminary report.
Demirci D; Tatlişen A; Ekmekçioğlu O; Ozcan N; Kaya R
Urol Int; 2004; 73(1):54-8. PubMed ID: 15263794
[TBL] [Abstract][Full Text] [Related]
15. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]